Filtered By:
Specialty: Cancer & Oncology
Cancer: Lung Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 651 results found since Jan 2013.

Upregulation of long non ‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib
In conclusion, the upregulation of LINC00460, the expression of which is implicated in osimertinib resistance, in the primary site and plasma of patients with EGFR mutation-positive lung cancer may be associated with a poor prognosis in those treated with osimertinib.PMID:37559586 | PMC:PMC10407845 | DOI:10.3892/ol.2023.13966
Source: Oncology Letters - August 10, 2023 Category: Cancer & Oncology Authors: Yuta Nakano Kazutoshi Isobe Takahiro Yoshizawa Naohisa Urabe Sakae Homma Kazuma Kishi Source Type: research

Cabazitaxel-loaded human serum albumin nanoparticles combined with TGF β-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer
ConclusionsThe antitumor effect of CTX-HSA-NPs on paclitaxel-resistant NSCLC was higher than that of CTX-Tween, and the toxicity was lower than that of CTX-Tween. TGF β-1 siRNA LNP can treat paclitaxel-resistant NSCLC by inhibiting the express ofTGF β-1 mRNA. The combined treatment of TGF β-1 siRNA LNP and CTX-HSA-NPs could effectively improve the antitumor efficacy of paclitaxel-resistant NSCLC. A combination therapy of chemotherapy and nucleic acid drugs could be an effective approach for treating paclitaxel-resistant NSCLC.
Source: Cancer Nanotechnology - July 29, 2023 Category: Cancer & Oncology Source Type: research

STAMBPL1 promotes the progression of lung adenocarcinoma by inhibiting DHRS2 expression
CONCLUSIONS: The expression of STAMBPL1 mRNA is significantly up-regulated in LUAD, promoting the progression of LUAD by down-regulating the expression of DHRS2 and acting as a potential biomarker of LUAD.PMID:37393834 | DOI:10.1016/j.tranon.2023.101728
Source: Translational Oncology - July 2, 2023 Category: Cancer & Oncology Authors: Xiang Yang Liqun Ling Changhong Li Tianqi Hu Chenkang Zhou Jian Chen Yumin Wang Lijuan Hu Source Type: research

Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer
ConclusionThe results showed that the PDL1-targeted albumin liposome could be used as a high efficient delivery vector of siRNA, and was a high efficient and safe nano vector for tumor targeted gene therapy.
Source: Journal of Cancer Research and Clinical Oncology - July 1, 2023 Category: Cancer & Oncology Source Type: research

Targeting transient receptor potential canonical 1 reduces non ‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling
In conclusion, the results of the current study suggested that targeting TRPC1 could attenuate cancer stemness and chemoresistance via suppression of PI3K/AKT signaling in NSCLC.PMID:37153044 | PMC:PMC10157351 | DOI:10.3892/ol.2023.13810
Source: Oncology Letters - May 8, 2023 Category: Cancer & Oncology Authors: Jiahui Jin Xinyu Yan Yaru Zhao Haojie Zhang Kai Zhuang Yating Wen Jingjing He Junzhen Gao Source Type: research

Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression
CONCLUSIONS: Our study identifies important gene regulatory functions for YAP/TAZ-TEAD-TP63 in the early stages of lung cancer development, which notably includes immune-suppressive roles, and suggest that an assessment of the activity of this transcriptional complex may offer a means to identify immune evasive bronchial PMLs and serve as a potential therapeutic target.PMID:37150829 | DOI:10.1186/s13046-023-02674-5
Source: Clinical Lung Cancer - May 7, 2023 Category: Cancer & Oncology Authors: Boting Ning Andrew M Tilston-Lunel Justice Simonetti Julia Hicks-Berthet Adeline Matschulat Roxana Pfefferkorn Avrum Spira Matthew Edwards Sarah Mazzilli Marc E Lenburg Jennifer E Beane Xaralabos Varelas Source Type: research

The kinesin light chain ‐2, a target of mRNA stabilizing protein HuR, inhibits p53 protein phosphorylation to promote radioresistance in NSCLC
ConclusionTaken together, these results indicated that HuR-KLC2 forms a positive feedback loop, which decreases the phosphorylation of p53 and thereby weaken the radiosensitivity of lung cancer cells. Our findings highlight the potential prognosis and therapeutic target value of KLC2 in lung cancer patients treated with radiotherapy.
Source: Thoracic Cancer - April 14, 2023 Category: Cancer & Oncology Authors: Simiao Qiao, Yuhang Jiang, Na Li, Xiaoxia Zhu Tags: ORIGINAL ARTICLE Source Type: research

PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize
CONCLUSION: PYCR1 has certain value in the diagnosis and prognosis of lung cancer. Moreover, through regulating JAK-STAT3 signaling pathway, PYCR1 significantly participated in process of lung cancer progression via the metabolism link between proline and glutamine, indicating that PYCR1 might be also a novel therapeutic target.PMID:37018868 | DOI:10.1016/j.tranon.2023.101667
Source: Translational Oncology - April 5, 2023 Category: Cancer & Oncology Authors: Lihong Zhang Xinyu Zhao Enqin Wang Ye Yang Liangfeng Hu Hongkun Xu Baojun Zhang Source Type: research